General MedicationsORALStandard
ALUNBRIG
BRIGATINIB
Standard Dose
90MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ALUNBRIG is listed in Drugs@FDA under application 208772 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BRIGATINIB Form and strength TABLET;ORAL - 90MG Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2022-02-28 00:00:00.
Structured Monograph
Clinical summary
Approval overview ALUNBRIG is listed in Drugs@FDA under application 208772 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BRIGATINIB Form and strength TABLET;ORAL - 90MG Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2022-02-28 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.